A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer Following Resistance to Initial EGFR Kinase Inhibitor

IRB/UVA Tracking #
19574
Contact
Gracie Hockenberry
Contact Email
mgt4n@virginia.edu
Contact Phone
1.434.297.7784
Phase
I
Primary purpose
Treatment
NCT
NCT02520778
Cancer PI
Ryan Gentzler
Status
OPEN TO ACCRUAL
Ages
Adult